[Treatment of cardiac failure with vasodilators (author's transl)].
D002301:Cardiac Glycosides / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006333:Heart Failure / Q000188:drug therapy*; D006830:Hydralazine / Q000627:therapeutic use; D007022:Hypotension / Q000139:chemically induced; D007548:Isosorbide Dinitrate / Q000627:therapeutic use; D005996:Nitroglycerin / Q000627:therapeutic use; D009599:Nitroprusside / Q000627:therapeutic use; D010643:Phenoxybenzamine / Q000627:therapeutic use; D010646:Phentolamine / Q000627:therapeutic use; D011224:Prazosin / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*
D002301:Cardiac Glycosides; D004232:Diuretics; D014665:Vasodilator Agents; D010643:Phenoxybenzamine; D009599:Nitroprusside; D006830:Hydralazine; D005996:Nitroglycerin; D007548:Isosorbide Dinitrate; D011224:Prazosin; D010646:Phentolamine
Die Behandlung der Herzinsuffizienz mit Vasodilatatoren.